Immunome, Inc. (IMNM) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
The consensus price target is $36.83 (low: $32.00, high: $40.00), representing an upside of 60.8% from the current price $22.90.
Analysts estimate Earnings Per Share (EPS) of $-4.38 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.00 vs est $-4.38 (missed -14.1%). 2025: actual $-2.43 vs est $-2.24 (missed -8.3%). Analyst accuracy: 90%.
IMNM Stock — 12-Month Price Forecast
$36.83
▲ +60.83% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Immunome, Inc., the average price target is $36.83, with a high forecast of $40.00, and a low forecast of $32.00.
The average price target represents a +60.83% change from the last price of $22.90.
Highest Price Target
$40.00
Average Price Target
$36.83
Lowest Price Target
$32.00
IMNM Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Immunome, Inc. in the past 3 months
EPS Estimates — IMNM
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.00
vs Est –$4.38
▼ 12.4% off
2025
Actual –$2.43
vs Est –$2.24
▼ 7.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IMNM
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.009B
vs Est $0.009B
▼ 4.0% off
2025
Actual $0.007B
vs Est $0.008B
▼ 11.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
